StreetInsider.com News Articles

Form 8-K Edesa Biotech, Inc. For: Jun 10

Thu, 11 Jun 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260611/26633585.html

Form 8-K Edesa Biotech, Inc. For: Jun 10

Thu, 11 Jun 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260611/26633585.html

Edesa Biotech raises $3.5 million in private placement led by CEO

Thu, 11 Jun 2026 09:15:25 -0400

Edesa Biotech Inc. (NASDAQ: EDSA) announced it entered into a securities purchase agreement for a private investment in public equity financing expected to generate gross proceeds of approximately $3.5 million before deducting offering expenses.

The clinical-stage biopharmaceutical company sold 729,241 common shares in the private placement. Investors paid $4.69 per share, while the company's chief executive officer paid $5.21 per share. The financing was completed without an agent, underwriter, broker or dealer.

Participants in the financing include Edesa's CEO and healthcare-focused investors. The transaction is expected to close on or about June 15, 2026, subject to customary closing conditions.

The company stated it

Edesa Biotech raises $3.5 million in private placement led by CEO

Thu, 11 Jun 2026 09:15:25 -0400

Participants in the financing include Edesa's CEO and healthcare-focused investors. The transaction is expected to close on or about June 15, 2026, subject to customary closing conditions.

The company stated it

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Thu, 11 Jun 2026 09:15:00 -0400

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $3.5 million to the Company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa’s Chief Executive Officer and healthcare-focused investors. The PIPE is

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Thu, 11 Jun 2026 09:15:00 -0400

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Thu, 11 Jun 2026 09:15:00 -0400

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Thu, 11 Jun 2026 09:15:00 -0400

Edesa Biotech reports exploratory data on drug for kidney injury

Fri, 05 Jun 2026 09:26:28 -0400

Edesa Biotech Inc. (NASDAQ: EDSA) reported exploratory data showing its drug paridiprubart reduced mortality in patients with acute kidney injury and respiratory distress. The company presented the findings at the 63rd European Renal Association Congress in Glasgow, Scotland.

The analysis included 101 patients with acute kidney injury from previous Phase 2 and Phase 3 studies of hospitalized patients with acute respiratory distress syndrome. Paridiprubart plus standard care treatments was associated with a 32% relative reduction in 28-day mortality compared to placebo plus standard care, according to the company's statement.

The adjusted 28-day mortality rate was 33% for patients receiving paridiprubart plus standard

Edesa Biotech reports exploratory data on drug for kidney injury

Fri, 05 Jun 2026 09:26:28 -0400

The adjusted 28-day mortality rate was 33% for patients receiving paridiprubart plus standard

Form 8-K Edesa Biotech, Inc. For: Jun 05

Fri, 05 Jun 2026 09:25:00 -0400

si-local-file:///var/storage/secattach/20260605/26609036.html

Form 8-K Edesa Biotech, Inc. For: Jun 05

Fri, 05 Jun 2026 09:25:00 -0400

si-local-file:///var/storage/secattach/20260605/26609036.html

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Fri, 05 Jun 2026 09:20:00 -0400

Analyses demonstrate consistent positive signals across endpoints in AKI patients
Findings derived from post hoc analysis of 101 patients also experiencing respiratory distress
New data and analysis to be presented today at the 63rd European Renal Association Congress

TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress.

The data, which expand upon previously reported Phase 3 clinical results through new exploratory analyses, will

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Fri, 05 Jun 2026 09:20:00 -0400

Analyses demonstrate consistent positive signals across endpoints in AKI patients
Findings derived from post hoc analysis of 101 patients also experiencing respiratory distress
New data and analysis to be presented today at the 63rd European Renal Association Congress

The data, which expand upon previously reported Phase 3 clinical results through new exploratory analyses, will

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Fri, 05 Jun 2026 09:20:00 -0400

Analyses demonstrate consistent positive signals across endpoints in AKI patients
Findings derived from post hoc analysis of 101 patients also experiencing respiratory distress
New data and analysis to be presented today at the 63rd European Renal Association Congress

The data, which expand upon previously reported Phase 3 clinical results through new exploratory analyses, will

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Fri, 05 Jun 2026 09:20:00 -0400

Analyses demonstrate consistent positive signals across endpoints in AKI patients
Findings derived from post hoc analysis of 101 patients also experiencing respiratory distress
New data and analysis to be presented today at the 63rd European Renal Association Congress

The data, which expand upon previously reported Phase 3 clinical results through new exploratory analyses, will

Form 4 Edesa Biotech, Inc. For: Jun 01 Filed by: Nijhawan Pardeep

Mon, 01 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26584831.html

Form 4 Edesa Biotech, Inc. For: Jun 01 Filed by: Nijhawan Pardeep

Mon, 01 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26584831.html

Form 4 Edesa Biotech, Inc. For: May 27 Filed by: Marshall Patrick

Fri, 29 May 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260529/26576348.html

Form 4 Edesa Biotech, Inc. For: May 27 Filed by: Marshall Patrick

Fri, 29 May 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260529/26576348.html

Form 4 Edesa Biotech, Inc. For: May 27 Filed by: Chypyha Joan

Fri, 29 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260529/26576336.html

Form 4 Edesa Biotech, Inc. For: May 27 Filed by: Chypyha Joan

Fri, 29 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260529/26576336.html

Form 4 Edesa Biotech, Inc. For: May 27 Filed by: MacDonald Sean Arthur

Fri, 29 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260529/26576342.html

Form 4 Edesa Biotech, Inc. For: May 27 Filed by: MacDonald Sean Arthur

Fri, 29 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260529/26576342.html

Form 4 Edesa Biotech, Inc. For: May 27 Filed by: Nijhawan Pardeep

Fri, 29 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260529/26576294.html